HEARTS-60+3评分:华法林长期治疗出血风险预测工具的开发与验证
本研究在泰国3家医院开展多中心回顾性队列研究,纳入二尖瓣狭窄合并房颤或机械心脏瓣膜且接受华法林≥3个月的患者,开发并验证HEARTS-60+3出血风险评分。推导队列1287例中出血事件发生率为4.92例/100患者年,评分C统计量为0.88(0.85-0.91);外部验证队列832例中出血发生率为4.31例/100患者年,C统计量为0.84(0.81-0.89)。
要点
- HEARTS-60+3评分用于预测MSAF或MHV患者华法林相关大出血风险。
- 推导队列C统计量0.88,外部验证C统计量0.84,判别能力良好。
- 评分包含8项预测因子,涵盖合并症、用药、实验室指标及TTR等。
核心结论
- HEARTS-60+3评分在MSAF或MHV长期华法林治疗患者中展现出作为出血风险预测工具的潜力。
研究设计与样本
- 多中心回顾性队列研究,在泰国3家医院开展,纳入2011-2015年间接受华法林≥3个月的成人MSAF或MHV患者。
- 推导队列1287例(随访3903.41患者年),外部验证队列832例(随访2018.45患者年)。
- 采用LASSO筛选变量,多变量logistic回归(逐步后退法)构建评分,C统计量评价判别能力,Hosmer-Lemeshow检验评价校准度。
主要发现
- 推导队列出血事件192例,发生率4.92例/100患者年。
- 推导队列C统计量(95%CI)为0.88(0.85-0.91)。
- 外部验证队列出血率4.31例/100患者年,C统计量(95%CI)为0.84(0.81-0.89)。
关键数值与推荐
- HEARTS-60+3评分包含:高血压/出血史;外部因素(如酒精/药物[阿司匹林或非甾体抗炎药]);贫血/低白蛋白血症;肾/肝功能不全;TTR<60%;卒中;年龄≥60岁;目标INR为3.0(2.5-3.5)。
临床怎么用
- 对于MSAF或MHV长期华法林治疗患者,可考虑使用HEARTS-60+3评分评估大出血风险,辅助临床决策。
局限性
- 回顾性研究设计可能存在信息偏倚。
- 研究仅在泰国3家医院开展,外推性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This study aimed to develop and validate a new bleeding risk score to predict warfarin-associated major bleeding for patients with mitral valve stenosis with atrial fibrillation (MSAF) or mechanical heart valves (MHV). METHODS: A multicentre, retrospective cohort study was conducted at 3 hospitals in Thailand. Adult patients with MSAF or MHV receiving warfarin for ≥3 months during 2011-2015 were identified. Data collection and case validation were performed electronically and manually. Potential variables were screened using the least absolute shrinkage and selection operator. Multivariate logistic regression analysis using stepwise backward selection was used to construct a risk score. Predictive discrimination of the score was evaluated using the C-statistic. Calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test. RESULTS: There were 1287 patients (3903.41 patient-year of follow-up), with 192 experiencing bleeding (4.92 event/100 patient-year) in the derivation cohort. A new bleeding risk score termed, the HEARTS-60 + 3 score (hypertension/history of bleeding; external factors, e.g., alcohol/drugs [aspirin or nonsteroidal anti-inflammatory drugs]; anaemia/hypoalbuminaemia; renal/hepatic insufficiency; time in therapeutic range of <60%; stroke; age ≥60 y; target international normalized ratio of 3.0 [2.5-3.5]), was developed and showed good predictive performance (C-statistic [95% confidence interval] of 0.88 [0.85-0.91]). In the external validation cohort of 832 patients (2018.45 patient-year with a bleeding rate of 4.31 event/100 patient-year), the HEARTS-60 + 3 score showed a good predictive performance with a C-statistic (95% confidence interval) of 0.84 (0.81-0.89). CONCLUSION: The HEARTS-60 + 3 score shows a potential as a bleeding risk prediction score in MSAF or MHV patients.
引用
- Phetroong S, Nathisuwan S, Chindavijak B, et al. Development and validation of a bleeding risk prediction score for patients with mitral valve stenosis and atrial fibrillation or mechanical heart valves receiving long-term warfarin therapy. Br J Clin Pharmacol. 2022. PMID: 36130484. doi:10.1111/bcp.15540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。